Pharmaceutical and Medical Biotechnology

Cost of Capital for Pharmaceutical , Biotechnology , and Medical Device

This study provides new estimates of systematic risk and the cost of equity capital for the pharmaceutical, biotechnology, and medical device sectors using data for firms with publicly-traded stock on U.S. exchanges during 2001-2005 and 2006-2008. Two frameworks are employed for estimating firms’ risk and the cost of equity capital: (1) the capital asset pricing model, and (2) the Fama-French t...

Biotechnologies: Current Achievements and Prospects Social Acceptance of Biotechnology-derived Products Medical and Pharmaceutical Biotechnology

Recent Trends in Pharmaceutical Biotechnology

The foundations of pharmaceutical biotechnology mainly lie in the capability of plants, microorganism and animals to produce low and high molecular weight compounds useful as therapeutics. Although molecules from plants and microorganisms are preferred extraction from plant biomass needs tedious downstream processing while in case of microorganisms it is easy with fewer amounts of impurities. P...

Pharmaceutical applications of biotechnology: promise and reality.

Biotechnology has continued to advance the state of the art in pharmaceutical research and discovery, especially in the generation and screening of molecular diversity [1]. Patents have begun to issue on both chemical [2] and biological [3] strategies for creating and evaluating libraries of compounds. Whether structured or random in design, these combinatorial collections, composed of natural ...

autistic disorders and medical biotechnology

autistic disorders (ads) are neuro-developmental disorders in the category of pervasive developmental disorders chiefly described by three main deficits: 1) deviant communication, 2) impaired reciprocal social interaction, and 3) limited, repetitive and stereotypic patterns of behaviors or interests 1. the world-wide prevalence of ads is estimated to be 62/10,000 1. although various treatment r...